AR080818A1 - Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos - Google Patents
Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanosInfo
- Publication number
- AR080818A1 AR080818A1 ARP110101094A ARP110101094A AR080818A1 AR 080818 A1 AR080818 A1 AR 080818A1 AR P110101094 A ARP110101094 A AR P110101094A AR P110101094 A ARP110101094 A AR P110101094A AR 080818 A1 AR080818 A1 AR 080818A1
- Authority
- AR
- Argentina
- Prior art keywords
- cytoskeleton
- agent
- composition according
- peptides
- vimentin
- Prior art date
Links
- 210000005260 human cell Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000010076 replication Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000004216 mammary stem cell Anatomy 0.000 title 1
- 210000004292 cytoskeleton Anatomy 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 208000031886 HIV Infections Diseases 0.000 abstract 3
- 208000037357 HIV infectious disease Diseases 0.000 abstract 3
- 102000013127 Vimentin Human genes 0.000 abstract 3
- 108010065472 Vimentin Proteins 0.000 abstract 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 3
- 230000002452 interceptive effect Effects 0.000 abstract 3
- 210000005048 vimentin Anatomy 0.000 abstract 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 abstract 2
- 108010065038 Keratin-10 Proteins 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- -1 lipid compounds Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000003963 intermediate filament Anatomy 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Un método para inhibir la replicacion del virus de la inmunodeficiencia humana (VIH) mediante la modulacion negativa o alteracion del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervencion sobre la estructura de estas proteínas causa una inhibicion de la replicacion del virus en células humanas. Además el uso de agentes, que comprenden péptidos y/o ARN interferentes y/o compuestos lipídicos, y producen la modulacion negativa o alteracion del citoesqueleto celular, para prevenir o tratar la infeccion por el VIH. Medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infeccion por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto. Reivindicacion 22: Una composicion farmacéutica para la prevencion o el tratamiento de la infeccion por el VIH que comprende un agente que altera los FI del citoesqueleto y un vehículo o excipiente farmacéuticamente aceptable. Reivindicacion 23: La composicion de acuerdo a la reivindicacion 22 donde dicho agente se selecciona del grupo compuesto por polipéptidos, péptidos, ácidos nucleicos y compuestos químicos que alteran los FI. Reivindicacion 24: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un péptido que se selecciona del grupo de los péptidos identificados como SEQ ID Ns:1 a la SEQ ID Ns:10, y homologos de los mismos. Reivindicacion 25: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un ARN interferente (iRNA) o un oligonucleotido antisentido dirigido a los genes de vimentina y/o de la queratina 10. Reivindicacion 28: La composicion de acuerdo a la reivindicacion 27 donde dicho compuesto lipídico es la prostaglandina ciclopentano 15 deoxy-delta-12.14-PGJ2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2010000056A CU23896B1 (es) | 2010-04-01 | 2010-04-01 | Método para inhibir la replicación del vih en células de mamíferos |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080818A1 true AR080818A1 (es) | 2012-05-09 |
Family
ID=44168763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101094A AR080818A1 (es) | 2010-04-01 | 2011-03-31 | Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos |
Country Status (16)
Country | Link |
---|---|
US (4) | US9205128B2 (es) |
EP (1) | EP2554550B1 (es) |
JP (2) | JP5925759B2 (es) |
KR (1) | KR101869917B1 (es) |
CN (1) | CN102884075B (es) |
AR (1) | AR080818A1 (es) |
AU (1) | AU2011235369B2 (es) |
BR (1) | BR112012025092B1 (es) |
CA (1) | CA2794930C (es) |
CU (1) | CU23896B1 (es) |
ES (1) | ES2604702T3 (es) |
MX (1) | MX2012011424A (es) |
MY (1) | MY161923A (es) |
RU (1) | RU2593948C2 (es) |
WO (1) | WO2011120474A1 (es) |
ZA (1) | ZA201207761B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102131041B1 (ko) | 2013-12-03 | 2020-07-08 | (주)아모레퍼시픽 | 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법 |
US9885021B2 (en) | 2014-06-12 | 2018-02-06 | Children's National Medical Center | Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use |
WO2016199964A1 (ko) * | 2015-06-10 | 2016-12-15 | 주식회사 이뮨메드 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
WO2016200220A1 (ko) * | 2015-06-10 | 2016-12-15 | 주식회사 이뮨메드 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
CU20200110A7 (es) * | 2020-12-23 | 2022-08-09 | Ct Ingenieria Genetica Biotecnologia | Péptidos para el tratamiento de infecciones respiratorias de origen viral |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
WO1998000542A2 (en) | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6476193B1 (en) * | 1998-10-06 | 2002-11-05 | Curagen Corporation | NLK1 protein and NLK1 protein complexes |
WO2001016322A2 (en) * | 1999-09-01 | 2001-03-08 | Subsidiary No. 3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
KR100607611B1 (ko) * | 2000-08-24 | 2006-08-02 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
US20040248296A1 (en) * | 2002-03-20 | 2004-12-09 | Beresford Paul J. | HIV therapeutic |
US7691582B2 (en) * | 2002-09-27 | 2010-04-06 | The Regents Of The University Of Michigan | Methods of secretory vimentin detection and modulation |
TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
WO2006111866A2 (en) * | 2005-03-08 | 2006-10-26 | Molmed Spa | Hiv vif mutants |
CA2671322A1 (en) * | 2005-12-02 | 2007-07-12 | Regents Of The University Of Colorado | Compositions and methods for treating actin-mediated medical conditions by administering an actin modulating agent |
CU23674A1 (es) * | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
-
2010
- 2010-04-01 CU CU2010000056A patent/CU23896B1/es active IP Right Grant
-
2011
- 2011-03-31 AR ARP110101094A patent/AR080818A1/es unknown
- 2011-04-01 WO PCT/CU2011/000001 patent/WO2011120474A1/es active Application Filing
- 2011-04-01 MY MYPI2012700711A patent/MY161923A/en unknown
- 2011-04-01 RU RU2012146542/10A patent/RU2593948C2/ru active
- 2011-04-01 BR BR112012025092-2A patent/BR112012025092B1/pt active IP Right Grant
- 2011-04-01 EP EP11720370.3A patent/EP2554550B1/en active Active
- 2011-04-01 CN CN201180023063.3A patent/CN102884075B/zh active Active
- 2011-04-01 ES ES11720370.3T patent/ES2604702T3/es active Active
- 2011-04-01 AU AU2011235369A patent/AU2011235369B2/en not_active Ceased
- 2011-04-01 KR KR1020127028726A patent/KR101869917B1/ko active IP Right Grant
- 2011-04-01 CA CA2794930A patent/CA2794930C/en active Active
- 2011-04-01 MX MX2012011424A patent/MX2012011424A/es unknown
- 2011-04-01 JP JP2013501620A patent/JP5925759B2/ja active Active
- 2011-04-01 US US13/637,845 patent/US9205128B2/en active Active
-
2012
- 2012-10-16 ZA ZA2012/07761A patent/ZA201207761B/en unknown
-
2015
- 2015-11-17 US US14/943,096 patent/US20160106810A1/en not_active Abandoned
- 2015-11-17 US US14/943,106 patent/US10434137B2/en active Active
- 2015-11-17 US US14/943,089 patent/US20160129073A1/en not_active Abandoned
-
2016
- 2016-02-03 JP JP2016019305A patent/JP6230635B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080818A1 (es) | Metodo para inhibir la replicacion del vih en celulas de mamiferos y en humanos | |
Chahar et al. | P-body components LSM1, GW182, DDX3, DDX6 and XRN1 are recruited to WNV replication sites and positively regulate viral replication | |
ES2640875T3 (es) | Método para la expresión de ARN celular | |
BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
Tang et al. | MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma | |
CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
ES2509890T3 (es) | Sustancias y composiciones para potenciar la reparación de ADN y procedimientos de uso | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
BR112012011381B8 (pt) | oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo | |
CR20220468A (es) | AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B (Divisional 2019-0056) | |
PE20211393A1 (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO | |
BR112013010525A2 (pt) | tratamento de hbv | |
PE20130314A1 (es) | PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO | |
JP2012136542A5 (es) | ||
EA202191537A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
RU2014146170A (ru) | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации | |
Xiao et al. | Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs | |
BR112018072198A2 (pt) | composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit | |
BR112018010535A2 (pt) | compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor | |
Yang et al. | Small interfering RNAs targeting the rabies virus nucleoprotein gene | |
AR123420A1 (es) | Inhibidores de dux4 y métodos de uso de estos | |
PE20230179A1 (es) | Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt) | |
AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
AR074027A1 (es) | Inhibicion de replicas de vih y de expresion de p-24 con elf-5a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |